{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"ALT OR AST > 3XULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"ALT OR AST> 5XULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"ALT OR AST> 10XULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"ALT OR AST > 20XULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"TOTAL BILIRUBIN > 2XULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS"}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase, AST = Aspartate Aminotransferase, ULN = Upper Limit of Normal.","groups":[{"description":"Four doses of nivolumab flat dose 240 mg IV were administered every 2 weeks (monotherapy phase), followed by 12 doses of the combination of AVD (adriamycin/ doxorubicin 25 mg/m2, vinblastine 6 mg/m2, dacarbazine 375 mg/m2) chemotherapy and nivolumab flat dose 240 mg IV for 6 cycles (combination phase).","id":"OG000","title":"Cohort D: Newly Diagnosed, Previously Untreated Advanced Stage cHL (Stage IIB, III and IV)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants treated in the Cohort D monotherapy phase","reportingStatus":"POSTED","timeFrame":"From first dose of monotherapy to 30 days after last dose of monotherapy phase (up to approximately 3 months)","title":"Number of Participants With Laboratory Abnormalities in Specific Liver Tests in Cohort D Monotherapy Phase","type":"SECONDARY","unitOfMeasure":"Participants"}